Switching from Insulin to Oral Sulfonylureas in Patients with Diabetes Due to Kir6.2 Mutations
Author(s) -
Ewan R. Pearson,
Isabelle Flechtner,
Pål R. Njølstad,
Maciej T. Małecki,
Sarah E. Flanagan,
Brian Larkin,
Frances M. Ashcroft,
I Klimeś,
Ethel Codner,
Violeta Iotova,
Annabelle S. Slingerland,
Julian HamiltonShield,
JeanJacques Robert,
Jens J. Holst,
Penny Clark,
Sian Ellard,
Oddmund Søvik,
Michel Polak,
Andrew T. Hattersley
Publication year - 2006
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa061759
Subject(s) - sulfonylurea , medicine , tolbutamide , endocrinology , insulin , sulfonylurea receptor , diabetes mellitus , kir6.2 , glibenclamide , glucagon , glycemic , type 2 diabetes , biology , protein subunit , biochemistry , gene
Heterozygous activating mutations in KCNJ11, encoding the Kir6.2 subunit of the ATP-sensitive potassium (K(ATP)) channel, cause 30 to 58 percent of cases of diabetes diagnosed in patients under six months of age. Patients present with ketoacidosis or severe hyperglycemia and are treated with insulin. Diabetes results from impaired insulin secretion caused by a failure of the beta-cell K(ATP) channel to close in response to increased intracellular ATP. Sulfonylureas close the K(ATP) channel by an ATP-independent route.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom